single-cell-analysis
(3)
Li Sun
Li Sun is the founder and CEO of Shennon Biotechnologies, a San Francisco single-cell immunotherapy company that profiles millions of immune cells in hours to pinpoint the rare T cells and antibody targets that fight cancer. A physicist by training (PhD from Harvard's Weitz lab, M.Eng from MIT), she spent five years as a deep-tech venture investor at Bessemer and Foundation Capital before building the platform herself. Shennon emerged from stealth in March 2023 with a $13M seed round led by DCVC.
LASE Innovation Inc.
LASE Innovation Inc. is a Boston-area techbio company commercializing LP™ Optical Cell Barcoding, a laser-particle technology that tags individual cells with narrowband light signatures tuned across more than 1,000 wavelengths. Spun out of the Wellman Center at Massachusetts General Hospital and MIT, the platform lets researchers run multiple passes of flow cytometry on the same sample, track the same cells over time, and connect single-cell data across flow, imaging and sequencing. The company is turning a long-standing limitation of flow cytometry - that you generally read a cell once and lose it - into a repeatable, trackable measurement.
Sheldon Kwok
Sheldon J.J. Kwok is the CEO and co-founder of LASE Innovation, a Boston-area techbio company turning microscopic lasers into cellular barcodes. He spent his PhD at MIT and Massachusetts General Hospital building particles that emit pure laser light from inside living cells, then spun the work into a company aiming to give every cell a trackable identity and add a time dimension to flow cytometry.